DDW has expanded. The longstanding first-choice publication for the drug discovery and development community now offers more content as well as more ways for you to access it. You told us what you wanted and we listened Established in 1999, DDW is the go-to brand for the industry. Following a… Read More
By FRAME (Fund for the Replacement of Animals in Medical Experiments) CEO, Celean Camp, FRAME Alternatives Laboratory Director, Dr Andrew Bennett and FRAME Scientific Liaison Officer, Amy Beale. Animals remain the first choice for testing and research in drug discovery and development, despite scientific advances across a range of… Read More
The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop… Read More
What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both… Read More
The multi-year process of drug discovery and development creates huge silos of data and information. Extracting and combining information can be a significant overhead, resulting in potential for delay and error. Iperion’s Duncan van Rijsbergen provides practical recommendations to help companies create high quality, consistent data that may be shared… Read More
Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially? More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly,… Read More
As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases… Read More
How do we know the medicines we take are safe and effective from batch to batch? Medicinal products like erythropoietin and gene therapies can be very challenging to quality control. Dr Mark Lies, Global Business Manager of Capillary Electrophoresis, SCIEX describes how capillary electrophoresis is being applied to address these… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the… Read More
By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known… Read More
The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop… Read More
By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways,… Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More